Department of Nuclear Medicine, Weifang People's Hospital, Shandong Province, People's Republic of China.
Clin Nucl Med. 2023 Aug 1;48(8):e371-e373. doi: 10.1097/RLU.0000000000004735. Epub 2023 Jun 6.
An 84-year-old man with prostate cancer with neuroendocrine differentiation underwent PET/CT for staging. 68 Ga-prostate-specific membrane antigen PET/CT did not show significant abnormal tracer accumulation, whereas 18 F-OC ( 18 F-AlF-NOTA-octreotide) PET/CT showed elevated tracer uptake at multiple sites throughout the body. Therefore, the patient opted to receive 1 cycle of 177 Lu-DOTATATE peptide receptor radionuclide therapy with a dose of 200 mCi. Encouragingly, radiographic tumor remission and improvement of clinical symptoms were observed after only 1 cycle of treatment.
一位 84 岁患有神经内分泌分化前列腺癌的男性患者进行了 PET/CT 分期。68Ga-前列腺特异性膜抗原 PET/CT 未见明显异常示踪剂聚集，而 18F-OC（18F-AIF-NOTA-奥曲肽）PET/CT 显示全身多处部位示踪剂摄取增加。因此，患者选择接受 1 个周期的 177Lu-DOTATATE 肽受体放射性核素治疗，剂量为 200mCi。令人鼓舞的是，仅接受 1 个周期的治疗后，影像学肿瘤缓解和临床症状改善。
